BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen-Plotkin AS, Albin R, Alcalay R, Babcock D, Bajaj V, Bowman D, Buko A, Cedarbaum J, Chelsky D, Cookson MR, Dawson TM, Dewey R, Foroud T, Frasier M, German D, Gwinn K, Huang X, Kopil C, Kremer T, Lasch S, Marek K, Marto JA, Merchant K, Mollenhauer B, Naito A, Potashkin J, Reimer A, Rosenthal LS, Saunders-Pullman R, Scherzer CR, Sherer T, Singleton A, Sutherland M, Thiele I, van der Brug M, Van Keuren-Jensen K, Vaillancourt D, Walt D, West A, Zhang J. Finding useful biomarkers for Parkinson's disease. Sci Transl Med 2018;10:eaam6003. [PMID: 30111645 DOI: 10.1126/scitranslmed.aam6003] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 14.7] [Reference Citation Analysis]
Number Citing Articles
1 Calvani R, Picca A, Landi G, Marini F, Biancolillo A, Coelho-Junior HJ, Gervasoni J, Persichilli S, Primiano A, Arcidiacono A, Urbani A, Bossola M, Bentivoglio AR, Cesari M, Bernabei R, Monaco MRL, Marzetti E. A novel multi-marker discovery approach identifies new serum biomarkers for Parkinson's disease in older people: an EXosomes in PArkiNson Disease (EXPAND) ancillary study. Geroscience 2020;42:1323-34. [PMID: 32458283 DOI: 10.1007/s11357-020-00192-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
2 Dawson VL, Dawson TM. Promising disease-modifying therapies for Parkinson's disease. Sci Transl Med 2019;11:eaba1659. [PMID: 31776289 DOI: 10.1126/scitranslmed.aba1659] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
3 Ugrumov M. Development of early diagnosis of Parkinson's disease: Illusion or reality? CNS Neurosci Ther 2020. [PMID: 32597012 DOI: 10.1111/cns.13429] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
4 Picca A, Guerra F, Calvani R, Romano R, Coelho-Júnior HJ, Bucci C, Marzetti E. Mitochondrial Dysfunction, Protein Misfolding and Neuroinflammation in Parkinson's Disease: Roads to Biomarker Discovery. Biomolecules 2021;11:1508. [PMID: 34680141 DOI: 10.3390/biom11101508] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Virreira Winter S, Karayel O, Strauss MT, Padmanabhan S, Surface M, Merchant K, Alcalay RN, Mann M. Urinary proteome profiling for stratifying patients with familial Parkinson's disease. EMBO Mol Med 2021;13:e13257. [PMID: 33481347 DOI: 10.15252/emmm.202013257] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
6 Comte V, Schmutz H, Chardin D, Orlhac F, Darcourt J, Humbert O. Development and validation of a radiomic model for the diagnosis of dopaminergic denervation on [18F]FDOPA PET/CT. Eur J Nucl Med Mol Imaging 2022. [PMID: 35567626 DOI: 10.1007/s00259-022-05816-7] [Reference Citation Analysis]
7 McKinnon C, Gros P, Lee DJ, Hamani C, Lozano AM, Kalia LV, Kalia SK. Deep brain stimulation: potential for neuroprotection. Ann Clin Transl Neurol 2019;6:174-85. [PMID: 30656196 DOI: 10.1002/acn3.682] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
8 Riley EA, Schekman R. Open science takes on Parkinson's disease. Elife 2021;10:e66546. [PMID: 33629954 DOI: 10.7554/eLife.66546] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Shihabuddin LS, Brundin P, Greenamyre JT, Stephenson D, Sardi SP. New Frontiers in Parkinson's Disease: From Genetics to the Clinic. J Neurosci 2018;38:9375-82. [PMID: 30381429 DOI: 10.1523/JNEUROSCI.1666-18.2018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
10 Leggio L, Paternò G, Vivarelli S, Falzone GG, Giachino C, Marchetti B, Iraci N. Extracellular Vesicles as Novel Diagnostic and Prognostic Biomarkers for Parkinson's Disease. Aging Dis 2021;12:1494-515. [PMID: 34527424 DOI: 10.14336/AD.2021.0527] [Reference Citation Analysis]
11 Stephenson D, Hill D, Cedarbaum JM, Tome M, Vamvakas S, Romero K, Conrado DJ, Dexter DT, Seibyl J, Jennings D, Nicholas T, Matthews D, Xie Z, Imam S, Maguire P, Russell D, Gordon MF, Stebbins GT, Somer E, Gallagher J, Roach A, Basseches P, Grosset D, Marek K; Critical Path for Parkinson’s Consortium. The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease. J Parkinsons Dis 2019;9:553-63. [PMID: 31306141 DOI: 10.3233/JPD-191648] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
12 Gan-Or Z, Rao T, Leveille E, Degroot C, Chouinard S, Cicchetti F, Dagher A, Das S, Desautels A, Drouin-Ouellet J, Durcan T, Gagnon JF, Genge A, Karamchandani J, Lafontaine AL, Sun SLW, Langlois M, Levesque M, Melmed C, Panisset M, Parent M, Poline JB, Postuma RB, Pourcher E, Rouleau GA, Sharp M, Monchi O, Dupré N, Fon EA. The Quebec Parkinson Network: A Researcher-Patient Matching Platform and Multimodal Biorepository. J Parkinsons Dis 2020;10:301-13. [PMID: 31868683 DOI: 10.3233/JPD-191775] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 18.0] [Reference Citation Analysis]
13 Brumberg J, Kerstens V, Cselényi Z, Svenningsson P, Sundgren M, Fazio P, Varrone A. Simplified quantification of [18F]FE-PE2I PET in Parkinson's disease: Discriminative power, test-retest reliability and longitudinal validity during early peak and late pseudo-equilibrium. J Cereb Blood Flow Metab 2021;41:1291-300. [PMID: 32955955 DOI: 10.1177/0271678X20958755] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Vieira SRL, Toffoli M, Campbell P, Schapira AHV. Biofluid Biomarkers in Parkinson's Disease: Clarity Amid Controversy. Mov Disord 2020;35:1128-33. [PMID: 32220025 DOI: 10.1002/mds.28030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Boucherie DM, Duarte GS, Machado T, Faustino PR, Sampaio C, Rascol O, Ferreira JJ. Parkinson's Disease Drug Development Since 1999: A Story of Repurposing and Relative Success. J Parkinsons Dis 2021;11:421-9. [PMID: 33459662 DOI: 10.3233/JPD-202184] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Lake J, Storm CS, Makarious MB, Bandres-Ciga S. Genetic and Transcriptomic Biomarkers in Neurodegenerative Diseases: Current Situation and the Road Ahead. Cells 2021;10:1030. [PMID: 33925602 DOI: 10.3390/cells10051030] [Reference Citation Analysis]
17 Surface M, Balwani M, Waters C, Haimovich A, Gan-Or Z, Marder KS, Hsieh T, Song L, Padmanabhan S, Hsieh F, Merchant KM, Alcalay RN. Reply to: No Evidence that Glucosylsphingosine Is a Biomarker for Parkinson Disease. Mov Disord 2022. [PMID: 35092096 DOI: 10.1002/mds.28936] [Reference Citation Analysis]
18 Huang J, Liu L, Qin L, Huang H, Li X. Weighted Gene Coexpression Network Analysis Uncovers Critical Genes and Pathways for Multiple Brain Regions in Parkinson's Disease. Biomed Res Int 2021;2021:6616434. [PMID: 33791366 DOI: 10.1155/2021/6616434] [Reference Citation Analysis]
19 Lokhov PG, Trifonova OP, Maslov DL, Lichtenberg S, Balashova EE. Diagnosis of Parkinson's Disease by A Metabolomics-Based Laboratory-Developed Test (LDT). Diagnostics (Basel) 2020;10:E332. [PMID: 32455603 DOI: 10.3390/diagnostics10050332] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
20 Vieira SRL, Schapira AHV. Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways. Free Radic Biol Med 2021;175:42-55. [PMID: 34450264 DOI: 10.1016/j.freeradbiomed.2021.08.230] [Reference Citation Analysis]
21 Lokhov PG, Maslov DL, Lichtenberg S, Trifonova OP, Balashova EE. Holistic Metabolomic Laboratory-Developed Test (LDT): Development and Use for the Diagnosis of Early-Stage Parkinson's Disease. Metabolites 2020;11:14. [PMID: 33383698 DOI: 10.3390/metabo11010014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Sardi SP, Simuni T. New Era in disease modification in Parkinson's disease: Review of genetically targeted therapeutics. Parkinsonism & Related Disorders 2019;59:32-8. [DOI: 10.1016/j.parkreldis.2018.10.025] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
23 Li T, Le W. Biomarkers for Parkinson's Disease: How Good Are They? Neurosci Bull 2020;36:183-94. [PMID: 31646434 DOI: 10.1007/s12264-019-00433-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
24 Chen-Plotkin AS, Zetterberg H. Updating Our Definitions of Parkinson's Disease for a Molecular Age. J Parkinsons Dis 2018;8:S53-7. [PMID: 30584165 DOI: 10.3233/JPD-181487] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
25 Jo DS, Cho DH. Peroxisomal dysfunction in neurodegenerative diseases. Arch Pharm Res 2019;42:393-406. [PMID: 30739266 DOI: 10.1007/s12272-019-01131-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
26 Pourzinal D, Yang JHJ, Bakker A, McMahon KL, Byrne GJ, Pontone GM, Mari Z, Dissanayaka NN. Hippocampal correlates of episodic memory in Parkinson's disease: A systematic review of magnetic resonance imaging studies. J Neurosci Res 2021;99:2097-116. [PMID: 34075634 DOI: 10.1002/jnr.24863] [Reference Citation Analysis]
27 Bonam SR, Tranchant C, Muller S. Autophagy-Lysosomal Pathway as Potential Therapeutic Target in Parkinson's Disease. Cells 2021;10:3547. [PMID: 34944054 DOI: 10.3390/cells10123547] [Reference Citation Analysis]
28 Jo DS, Park NY, Cho DH. Peroxisome quality control and dysregulated lipid metabolism in neurodegenerative diseases. Exp Mol Med 2020;52:1486-95. [PMID: 32917959 DOI: 10.1038/s12276-020-00503-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
29 Zhou X, Liu Z, Zhou X, Xiang Y, Zhou Z, Zhao Y, Pan H, Xu Q, Chen Y, Sun Q, Wu X, Tan H, Li B, Yuan K, Xie Y, Liao W, Hu S, Zhu J, Wu X, Li J, Wang C, Lei L, Tang J, Liu Y, Wu H, Huang W, Wang T, Xue Z, Wang P, Zhang Z, Xu P, Chen L, Wang Q, Wang X, Cheng O, Shen Y, Liu W, Ye M, You Y, Li J, Yan X, Guo J, Tang B; for Parkinson's Disease & Movement Disorders Multicenter Database and Collaborative Network in China (PD-MDCNC). The Chinese Parkinson's Disease Registry (CPDR): Study Design and Baseline Patient Characteristics. Mov Disord 2022. [PMID: 35503029 DOI: 10.1002/mds.29037] [Reference Citation Analysis]
30 Lualdi M, Ronci M, Zilocchi M, Corno F, Turilli ES, Sponchiado M, Aceto A, Alberio T, Fasano M. Exploring the Mitochondrial Degradome by the TAILS Proteomics Approach in a Cellular Model of Parkinson's Disease. Front Aging Neurosci 2019;11:195. [PMID: 31417398 DOI: 10.3389/fnagi.2019.00195] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Feraco P, Gagliardo C, La Tona G, Bruno E, D'angelo C, Marrale M, Del Poggio A, Malaguti MC, Geraci L, Baschi R, Petralia B, Midiri M, Monastero R. Imaging of Substantia Nigra in Parkinson's Disease: A Narrative Review. Brain Sci 2021;11:769. [PMID: 34207681 DOI: 10.3390/brainsci11060769] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Chen J, Yang T, Song S, Liu Q, Sun Y, Zhao L, Fu Z, Wang MJ, Hu YP, Chen F. Senescence suppressed proliferation of host hepatocytes is precondition for liver repopulation. Biochem Biophys Res Commun 2019;516:591-8. [PMID: 31239154 DOI: 10.1016/j.bbrc.2019.06.103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
33 Wu J, Guo T, Zhou C, Gao T, Guan X, Xuan M, Gu Q, Huang P, Song Z, Xu X, Zhang M. Disrupted interhemispheric coordination with unaffected lateralization of global eigenvector centrality characterizes hemiparkinsonism. Brain Res 2020;1742:146888. [PMID: 32439342 DOI: 10.1016/j.brainres.2020.146888] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Bargar C, Wang W, Gunzler SA, LeFevre A, Wang Z, Lerner AJ, Singh N, Tatsuoka C, Appleby B, Zhu X, Xu R, Haroutunian V, Zou WQ, Ma J, Chen SG. Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson's disease and dementia with Lewy bodies. Acta Neuropathol Commun 2021;9:62. [PMID: 33827706 DOI: 10.1186/s40478-021-01175-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Mo M, Tang Y, Wei L, Qiu J, Peng G, Lin Y, Zhou M, Dai W, Zhang Z, Chen X, Liu H, Ding L, Ye P, Wu Y, Zhu X, Wu Z, Guo W, Xu P. Soluble Triggering Receptor Expressed on Myeloid Cells 2 From Cerebrospinal Fluid in Sleep Disorders Related to Parkinson's Disease. Front Aging Neurosci 2021;13:753210. [PMID: 34658845 DOI: 10.3389/fnagi.2021.753210] [Reference Citation Analysis]
36 Ma LZ, Zhang C, Wang H, Ma YH, Shen XN, Wang J, Tan L, Dong Q, Yu JT. Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson's Disease. J Parkinsons Dis 2021;11:1117-27. [PMID: 33935105 DOI: 10.3233/JPD-212535] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Pirooznia SK, Rosenthal LS, Dawson VL, Dawson TM. Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection. Pharmacol Rev 2021;73:33-97. [PMID: 34663684 DOI: 10.1124/pharmrev.120.000189] [Reference Citation Analysis]
38 Aderemi AV, Ayeleso AO, Oyedapo OO, Mukwevho E. Metabolomics: A Scoping Review of Its Role as a Tool for Disease Biomarker Discovery in Selected Non-Communicable Diseases. Metabolites 2021;11:418. [PMID: 34201929 DOI: 10.3390/metabo11070418] [Reference Citation Analysis]
39 Schneider RB, Omberg L, Macklin EA, Daeschler M, Bataille L, Anthwal S, Myers TL, Baloga E, Duquette S, Snyder P, Amodeo K, Tarolli CG, Adams JL, Callahan KF, Gottesman J, Kopil CM, Lungu C, Ascherio A, Beck JC, Biglan K, Espay AJ, Tanner C, Oakes D, Shoulson I, Novak D, Kayson E, Ray Dorsey E, Mangravite L, Schwarzschild MA, Simuni T; Parkinson Study Group AT-HOME PD Investigators. Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD). Ann Clin Transl Neurol 2021;8:308-20. [PMID: 33350601 DOI: 10.1002/acn3.51236] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
40 Söderbom G. Status and future directions of clinical trials in Parkinson's disease. Int Rev Neurobiol 2020;154:153-88. [PMID: 32739003 DOI: 10.1016/bs.irn.2020.02.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Wang Z, Becker K, Donadio V, Siedlak S, Yuan J, Rezaee M, Incensi A, Kuzkina A, Orrú CD, Tatsuoka C, Liguori R, Gunzler SA, Caughey B, Jimenez-Capdeville ME, Zhu X, Doppler K, Cui L, Chen SG, Ma J, Zou WQ. Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease. JAMA Neurol 2020. [PMID: 32986090 DOI: 10.1001/jamaneurol.2020.3311] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 8.5] [Reference Citation Analysis]
42 Xiong XF, Chen DD, Zhu HJ, Ge WH. Prognostic value of endogenous and exogenous metabolites in liver transplantation. Biomark Med 2020;14:1165-81. [PMID: 32969246 DOI: 10.2217/bmm-2020-0073] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Cookson MR. Proteomics: techniques and applications in neuroscience. J Neurochem 2019;151:394-6. [PMID: 31625157 DOI: 10.1111/jnc.14867] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Wang J, Xu X, Shi X, Zhang J, Gao F, Li J, Jia S, Xu J, Zhang J, Peng L, Li L, Chen J, Li S, Lu L. Literature-based learning and experimental design model in molecular biology teaching for medical students at Tongji University. Biochem Mol Biol Educ 2021;49:189-97. [PMID: 32881259 DOI: 10.1002/bmb.21419] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Posavi M, Diaz-Ortiz M, Liu B, Swanson CR, Skrinak RT, Hernandez-Con P, Amado DA, Fullard M, Rick J, Siderowf A, Weintraub D, McCluskey L, Trojanowski JQ, Dewey RB Jr, Huang X, Chen-Plotkin AS. Characterization of Parkinson's disease using blood-based biomarkers: A multicohort proteomic analysis. PLoS Med 2019;16:e1002931. [PMID: 31603904 DOI: 10.1371/journal.pmed.1002931] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]